Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$587 Mln
P/E Ratio
--
P/B Ratio
5.89
Industry P/E
--
Debt to Equity
0.01
ROE
-0.53 %
ROCE
-51.92 %
Div. Yield
0 %
Book Value
0.98
EPS
-0.47
CFO
$-178.38 Mln
EBITDA
$-184.16 Mln
Net Profit
$-195.46 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Trevi Therapeutics Inc (TRVI)
| 52.18 | -3.09 | 65.87 | 113.27 | 23.36 | 18.89 | -- |
|
BSE Sensex*
| 2.20 | 3.98 | 4.51 | 8.45 | 11.82 | 20.21 | 11.17 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
Trevi Therapeutics Inc (TRVI)
| 204.66 | -30.57 | 146.80 | -67.69 | -35.47 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.78 | 9,808.03 | 20.22 | 23.13 | |
| 290.25 | 8,956.09 | 22.08 | 58.42 | |
| 26.54 | 9,559.25 | -- | -28.77 | |
| 103.22 | 10,030.35 | 30.81 | 14.16 |
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough... conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is based in New Haven, Connecticut. Address: 195 Church Street, New Haven, CT, United States, 06510 Read more
Co-Founder, CEO, President & Director
Ms. Jennifer L. Good
Co-Founder, CEO, President & Director
Ms. Jennifer L. Good
Headquarters
New Haven, CT
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Trevi Therapeutics Inc (TRVI) stood at $ 111 Mln as on 31-Dec-24
The share price of Trevi Therapeutics Inc (TRVI) is $6.27 (NASDAQ) as of 23-Apr-2025 16:00 EDT. Trevi Therapeutics Inc (TRVI) has given a return of 23.36% in the last 3 years.
Trevi Therapeutics Inc (TRVI) has a market capitalisation of $ 587 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Trevi Therapeutics Inc (TRVI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Trevi Therapeutics Inc (TRVI) and enter the required number of quantities and click on buy to purchase the shares of Trevi Therapeutics Inc (TRVI).
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is based in New Haven, Connecticut. Address: 195 Church Street, New Haven, CT, United States, 06510
The CEO & director of Ms. Jennifer L. Good. is Trevi Therapeutics Inc (TRVI), and CFO & Sr. VP is Ms. Jennifer L. Good.
There is no promoter pledging in Trevi Therapeutics Inc (TRVI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Trevi Therapeutics Inc (TRVI) | Ratios |
|---|---|
|
Return on equity(%)
|
-52.59
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Trevi Therapeutics Inc (TRVI) was $0 Mln.
$0.20
(
